VONVENDI

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
VONVENDI
Generic name
VON WILLEBRAND FACTOR (RECOMBINANT)
Manufacturer
Takeda Pharmaceuticals America, Inc.
Product type
PLASMA DERIVATIVE
SPL set ID
53b6d198-6175-4a26-8606-dc0d2a0f12d6
SPL ID
211b7afb-6928-402b-bb78-b7fa6c5c96fe
Version
21
Effective date
2026-07-28
Source export date
2026-11-13
Source partition
2
Source file
https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:31:45

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Thromboembolic events have occurred with VONVENDI. Patients with known risk factors for thrombosis are at higher risk. Monitor for early signs of thrombosis and have prophylaxis measures against thromboembolism instituted according to current recommendations. In patients requiring frequent doses of VONVENDI in combination with recombinant factor VIII, monitor plasma levels for FVIII:C because sustained excessive factor VIII plasma levels can increase the risk for thromboembolic events. ( 5.1 ) Hypersensitivity and infusion-related reactions, including anaphylaxis, may occur. Discontinue VONVENDI if hypersensitivity symptoms occur and administer appropriate emergency treatment. ( 5.2 ) Neutralizing antibodies to von Willebrand factor (VWF) and/or factor VIII can occur with VONVENDI. If the expected plasma levels of VWF activity (VWF:RCo) are not attained, or if bleeding is not controlled with an appropriate dose, perform an appropriate assay to determine if an anti-VWF or anti-factor VIII inhibitors are present. ( 5.3 ) 5.1 Thromboembolic Events Thromboembolic events have occurred with VONVENDI [see Adverse Reactions (6.1) ] . These events can include disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke. Patients with known risk factors for thrombosis, including low ADAMTS13 levels, are at a higher risk [see Description (11) ] . Monitor patients for signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope. Institute prophylaxis measures against thromboembolism according to current clinical practice and standard of care. In patients requiring frequent doses of VONVENDI in combination with rFVIII, monitor plasma levels for FVIII:C activity because sustained excessive factor VIII plasma levels can increase the risk of thromboembolic complications. 5.2 Hypersensitivity and Infusion-Related Reactions Hypersensitivity reactions and infusion-related reactions have occurred with VONVENDI [see Adverse Reactions (6.1) . These reactions can include anaphylactic shock, generalized urticaria, angioedema, chest tightness, hypotension, shock, lethargy, nausea, vomiting, paresthesia, pruritus, restlessness, blurred vision, wheezing and/or acute respiratory distress. If signs and symptoms of severe allergic reactions occur, immediately discontinue administration of VONVENDI and provide appropriate supportive care. VONVENDI contains trace amounts of mouse immunoglobulin G (MuIgG) and hamster proteins less than or equal to 2 ng/IU VONVENDI. Patients treated with this product may develop hypersensitivity reactions to non-human mammalian proteins. 5.3 Neutralizing Antibodies Neutralizing antibodies to VWF and/or factor VIII can occur with VONVENDI. If the expected plasma levels of VWF activity (VWF:RCo) are not attained, perform an appropriate assay to determine if anti-VWF or anti-factor VIII inhibitors are present. Consider other therapeutic options and direct the patient to a physician with experience in the care of either VWD or hemophilia A. In patients with high levels of inhibitors to VWF or factor VIII, VONVENDI therapy may not be effective, and infusion of this protein may lead to severe hypersensitivity reactions. Since inhibitor antibodies can occur concomitantly with anaphylactic reactions, evaluate patients experiencing an anaphylactic reaction for the presence of inhibitors. 5.4 Monitoring Laboratory Tests Monitor plasma levels of VWF:RCo and factor VIII activities in patients receiving VONVENDI to avoid sustained excessive VWF and/or factor VIII activity levels, which may increase the risk of thrombotic events, particularly in patients with known clinical or laboratory risk factors. Monitor for development of VWF and/or factor VIII inhibitors when suspected. Perform appropriate inhibitor assays to determine if VWF and/or factor VIII inhibitors are present if bleeding is not controlled with the expected dose of VONVENDI.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions observed (≥2% of patients) were headache, vomiting, nausea, dizziness and generalized pruritus. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety data described in this section reflects exposure of VONVENDI in six clinical studies (Study 1, Study 2, Study 3, Study 4, Study 5 and Study 6) in patients with von Willebrand Disease (VWD). A total of 103 adult and 29 pediatric patients received intravenous infusion of VONVENDI with or without rFVIII with a median dose of 311 IU/kg per patient (range of 2 to 29593 IU/kg). The patients were followed for up to 4.6 years. The most common adverse reactions observed in greater than or equal to 2% of patients in clinical trials with VONVENDI (n=132) were headache, vomiting, nausea, dizziness and generalized pruritus. Table 5 lists the adverse reactions reported with VONVENDI from pooled safety population from six clinical studies. Table 5: Adverse Reactions System Organ Class (SOC) Adverse Reaction Total (N=132) n (%) Cardiac Disorders Tachycardia 1 (0.8%) Gastrointestinal Disorders Vomiting 9 (7%) - Nausea 7 (5%) General Disorders and Administration Site Conditions Infusion site paresthesia 1 (0.8%) - Infusion-related reaction One patient developed infusion-related reaction experiencing chest discomfort and increased heart rate. 1 (0.8%) Skin and Subcutaneous Tissues Disorders Generalized pruritus 3 (2%) Vascular Disorders Hypertension 2 (2%) - Hot flush 1 (0.8%) - Deep vein thrombosis 1 (0.8%) Nervous System Disorders Headache 18 (14%) - Dizziness 4 (3%) - Vertigo 2 (2%) - Dysgeusia 1 (0.8%) - Tremor 1 (0.8%) Investigations Electrocardiogram T wave inversions 1 (0.8%) 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of VONVENDI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders : Hypersensitivity including anaphylactic reaction; Infusion-related reaction.

adverse reactions table

<table width="90%" ID="Table5"><caption>Table 5: Adverse Reactions</caption><col width="40%" align="left" valign="top"/><col width="30%" align="left" valign="middle"/><col width="30%" align="center" valign="middle"/><thead><tr><th styleCode="Lrule Rrule" align="center" valign="middle">System Organ Class (SOC)</th><th styleCode="Rrule" align="center">Adverse Reaction</th><th styleCode="Rrule">Total (N=132) n (%)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Cardiac Disorders</content></td><td styleCode="Rrule">Tachycardia</td><td styleCode="Rrule">1 (0.8%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Gastrointestinal Disorders</content></td><td styleCode="Rrule">Vomiting</td><td styleCode="Rrule">9 (7%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">-</td><td styleCode="Rrule">Nausea</td><td styleCode="Rrule" align="center">7 (5%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">General Disorders and Administration Site Conditions</content></td><td styleCode="Rrule">Infusion site paresthesia</td><td styleCode="Rrule">1 (0.8%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">-</td><td styleCode="Rrule">Infusion-related reaction<footnote>One patient developed infusion-related reaction experiencing chest discomfort and increased heart rate.</footnote></td><td styleCode="Rrule" align="center">1 (0.8%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Skin and Subcutaneous Tissues Disorders</content></td><td styleCode="Rrule">Generalized pruritus</td><td styleCode="Rrule">3 (2%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Vascular Disorders</content></td><td styleCode="Rrule">Hypertension</td><td styleCode="Rrule">2 (2%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">-</td><td styleCode="Rrule">Hot flush</td><td styleCode="Rrule" align="center">1 (0.8%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">-</td><td styleCode="Rrule">Deep vein thrombosis</td><td styleCode="Rrule" align="center">1 (0.8%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Nervous System Disorders</content></td><td styleCode="Rrule">Headache</td><td styleCode="Rrule">18 (14%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">-</td><td styleCode="Rrule">Dizziness</td><td styleCode="Rrule" align="center">4 (3%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">-</td><td styleCode="Rrule">Vertigo</td><td styleCode="Rrule" align="center">2 (2%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">-</td><td styleCode="Rrule">Dysgeusia</td><td styleCode="Rrule" align="center">1 (0.8%)</td></tr><tr styleCode="Botrule"><td styleCode="Rrule Lrule">-</td><td styleCode="Rrule">Tremor</td><td styleCode="Rrule" align="center">1 (0.8%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Investigations</content></td><td styleCode="Rrule">Electrocardiogram T wave inversions</td><td styleCode="Rrule" align="center">1 (0.8%)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.